Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anca Bulgaru

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Breast Imaging|February 28, 2024
Decreasing the Interval Wait Times for Screening Mammogram Results Using the "Reflex Testing" AlgorithmJulio Alvarenga, Jay Moran, Anca Bulgaru, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeuticsWenJing Liu, Anca Bulgaru, Missak Haigentz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumorsSanjay Goel, Kavita Desai, Anca Bulgaru, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Breast Imaging|February 28, 2024
Decreasing the Interval Wait Times for Screening Mammogram Results Using the "Reflex Testing" AlgorithmJulio Alvarenga, Jay Moran, Anca Bulgaru, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeuticsWenJing Liu, Anca Bulgaru, Missak Haigentz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumorsSanjay Goel, Kavita Desai, Anca Bulgaru, et al.
Investigational New Drugs|January 2, 2007
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancersSanjay Goel, Kavita Desai, Sirisha Karri, et al.
Pageof 1